Videos

Neeraj Agarwal, MD, discusses the safety profile of olaparib in homologous recombination repair gene-mutated metastatic castration-resistant prostate cancer.  


Dr. Agarwal on the Safety Profile of Olaparib in HRR Gene-Mutant mCRPC 

Neeraj Agarwal, MD, director of the Genitourinary Oncology Program, Oncology Division, professor of medicine, physician, and investigator, at Huntsman Cancer Institute, discusses data with the combination of cabozantinib (Cabometyx) and atezolizumab (Tecentriq) in patients with metastatic castration-resistant prostate cancer (mCRPC).

Dr. Agarwal on Data With Cabozantinib/Atezolizumab in mCRPC

Neeraj Agarwal, MD, discusses the tolerability of apalutamide in metastatic castration-sensitive prostate cancer.



Dr. Agarwal on the Tolerability of Apalutamide in mCSPC

Articles

Neeraj Agarwal, MD, discusses the implications of the PFS2 data from the TITAN trial in metastatic castration-sensitive prostate cancer.

Early Intensification With Apalutamide Is Key in Metastatic Castration-Sensitive Prostate Cancer

Neeraj Agarwal, MD, discusses data from a posthoc analysis of the phase III TITAN trial in patients with metastatic castration-sensitive prostate cancer.

Dr. Agarwal on PFS2 Data From the TITAN Trial in mCSPC

Neeraj Agarwal, MD, discusses the safety profile ofcabozantinib and atezolizumab in patients with metastatic castration-resistant prostate cancer.

Huntsman Cancer Institute

Latest from Huntsman Cancer Institute

New content coming soon, please check back later.